Abstract:
Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I): wherein R₁ is CH₃, CH₂OH, or CH₃CH₂OR; or aryl or heteroaryl optionally substituted with one or more groups R₂; R₃ is alkyl or is part of a ring with R₂; R₄ is an alkyl or is part of a ring with R₂; R₅ is aryl or heteroaryl optionally substituted with R₂; each R₂ is independently alkyl, CF₃, OH, Oalkyl, OCOalkyl, CONH₂, CN, halogen, NH₂, NO₂, NHCHO. NHCONH₂, NH₂SO₃alkyl, CONH₂SO₃Me, SO₂NH₂, Salkyl, CH₂SO₃alkyl or OCONalkyl; R₃ is OR₁ or (CH₂)₃OR₂R₃ CF₃, OR₂, OR₃, OCOOR₂, COOR₂, CONH₂, CH₂CONH₂, CN, halogen, NH₂,
NO₂, NHCHO, NHCONH₂, NH₂CONH₂, NHCONCHR₂, NHCONCHR₃, NHCOOR₂, NHCOOaryl, NHSO₃alkyl, NHSO₃Me, CONH₂SO₃Me. SO₃Me or SO₂NH₂; R₈ is (CH₂)₄OR₂, (CH₃)₃COOR₂ or (CH₂)₆COaryl; R₉ is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof.

Title: 2-AMINOALCOHOLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
2-AMINOALCOHOLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Field of the Invention
This invention relates to the treatment of neurodegenerative diseases.

Background of the Invention

Neurodegenerative diseases are conditions that affect brain or peripheral nerve function. They result from the deterioration of neurons and they are characterised by progressive central or peripheral nervous dysfunction. They are divided into two groups: conditions causing problems with movement or sensation and conditions affecting memory or related to dementia. Neurodegenerative diseases include: Alexander disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Refsum's disease, Sandhoff disease, Schilder's disease, Steele-Richardson-Olszewski disease, tabes dorsalis and Guillain-Barre Syndrome. Currently there are no effective cures for these conditions, and very few treatments are available.

Summary of the Invention

Surprisingly, it has been found that beta-amino alcohols are useful for the treatment of neurodegenerative diseases. The beta-amino alcohols are of formula (I)

\[
\begin{align*}
\text{OH} & \quad \text{H} \\
R_1 & \quad N \quad R_2 \\
R_3 & \quad \text{(I)}
\end{align*}
\]

wherein

- \( R_1 \) is \( \text{CHR}_4\text{OR}_5 \) or \( \text{CHR}_4\text{SR}_5 \), or aryl or heteroaryl optionally substituted with one or more groups \( R_6 \);
- \( R_2 \) is alkyl or is part of a ring with \( R_3 \);
- \( R_3 \) is \( \text{H} \), alkyl or \( \text{CH}_2 \) (when forming part of a ring with \( R_2 \));
- \( R_4 \) is \( \text{H} \) or alkyl or is part of a ring with \( R_5 \);
- \( R_5 \) is aryl or heteroaryl optionally substituted with \( R_7 \);
each R₆ is independently alkyl, CF₃, OH, Oalkyl, OCOalkyl, CONH₂, CN, halogen, NH₂, NO₂, NHCHO, NHCONH₂, NHSO₂alkyl, CONH₂, SOMe, SO₂NH₂, Salkyl, CH₂SO₂alkyl or COCONalkyl₂:

R₇ is R₈ or (CHₐ)ₙOR₈, R₉, CF₃, OH, OR₉, OCO₉, COR₉, COOR₉, CONH₂;

CH₂CONH₂, CN, halogen, NH₂, NO₂, NHCHO, NHCONH₂, NHCONHR₂, NHCOR₉, NHCOaryl, NHSO₂Me, CONH₂, SME, SOMe or SO₂NH₂;

R₈ is (CH₂)ₙOR₉, (CHₐ)ₙOR₉, (CH₂)ₙCOOR₉ or (CH₂)ₙCOaryl;

R₉ is alkyl or cycloalkyl; and

n is 1 to 4;

or a salt thereof.

Description of the Drawing

Fig. 1 is a graph showing the effects of (+)-erythro2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride (Example 1) and Copaxone on neurological scores induced in a model.

Description of the Invention

It is understood that the invention refers to salts, e.g. the hydrochloride, metabolites and pro-drugs thereof, as well as any diastereomers and enantiomers of (I).

Some of the compounds of formula (I) have antihypertensive, vasodilator, sympathomimetic, bronchodilator or cardiostimulant activity through agonism and antagonism at alpha and beta adrenoceptors. These agents have at least one chiral centre and their activity at the alpha or beta adrenoceptors resides mainly or solely in one of the enantiomers. If the molecule has more than one chiral centre, the activity at the alpha or beta adrenoceptors resides mainly in one of the diastereomers.

The preferred diastereomer or enantiomer of (I) has little or no activity at the α or β adrenoceptors. This activity may be determined by use of the appropriate in vitro assay.

The compounds of formula (I) according to the invention are useful to treat neurodegenerative diseases including Alexander disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, Parkinson's disease, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Refsum's disease, Sandhoff disease, Schilder's disease, Steele-Richardson-Olszewski disease, tabes dorsalis or Guillain-Barre Syndrome.

Compounds of formula (I) may be used according to the invention alone, in combination with another therapeutic agent, or in treatment of a patient also being
administered another therapeutic agent. Such other agents include cholinesterase inhibitors (examples including galantamine, rivastigmine, donepezil, tacrine), steroids, interferons and glutamate receptor agents such as AMPA, kainate agents and NMDA antagonists (examples including memantine).

Any suitable route of administration can be used. For example, any of oral, topical, parenteral, intracerebroventricular, spinal, ocular, rectal, vaginal, inhalation, buccal, sublingual and intranasal delivery routes may be suitable. The dose of the active agent will depend on the nature and degree of the condition, the age and condition of the patient and other factors known to those skilled in the art. A typical dose is 0.1-100 mg given one to three times per day.

The following Example illustrates the invention.

Example

Experimental Allergic Encephalomyelitis (EAE) is a central nervous system, autoimmune, demyelinating disease, that mimics many aspects of multiple sclerosis. Acute models of murine EAE are often utilised to evaluate the efficacy of therapeutics.

Method

Acclimatised SJL mice were sensitised by a subcutaneous injection proteolipid protein (PLP) in Freund's complete adjuvant (CFA) acting as an encephalitogenic inoculum. Innoculum was administered subcutaneously at a concentration of 125 µg PLP/300 µg CFA in a volume of 200 µl. 48 hours later, an intraperitoneal injection of pertussis toxin (PTX) was administered at a dose of 20 µg/kg, to increase blood-brain barrier permeability.

(+)-E/yr-2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride and copoxane were administered from the first day of the experiment and once a day until the end. (+)-Ery#7ro-2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride was administered orally at a dose of 10 mg/kg. Copoxone was administered intraperitoneally at a dose of 25 mg/kg. Throughout the experiment, careful clinical examinations and body weights were taken to observe the well being of the animal. In addition, clinical scoring of the EAE symptoms was taken to the classical 0-5 scale, as follows:

<table>
<thead>
<tr>
<th>Score</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal reactions</td>
</tr>
<tr>
<td>1</td>
<td>Tail weakness</td>
</tr>
<tr>
<td>2</td>
<td>Hind leg weakness and paresis</td>
</tr>
<tr>
<td>3</td>
<td>Hind leg paralysis</td>
</tr>
<tr>
<td>4</td>
<td>Quadriplegia</td>
</tr>
<tr>
<td>5</td>
<td>Moribund/death</td>
</tr>
</tbody>
</table>
Results

Figure 1 describes the effect of orally administered (+)-erythropo2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride (10 mg/kg) and intraperitoneal^ administered Copaxone (25 mg/kg) versus the vehicle control (for (+)-erythro-2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride) on SJL mouse EAE neurological scores.

EAE-induced mice exhibited pronounced neurological deficits as defined by the vehicle group. Weaknesses in hind limb were recorded by day 10 and peaked at day 17 with a maximum neurological deficits score of 2; which relates to deficits in walking and unsteady gait.

(+)-E/yrho2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride showed no improvement in the maximal neurologic score, but exhibited a more rapid improvement in symptoms, accelerating disease resolution compared to the vehicle.

Copaxone delayed the onset of neurological symptoms by 2-3 days, but had no effect on the improvement of symptoms, seemingly worsening this aspect of the model.

These data show that (+)-erythro-2-tert-butylamino-1-(3-chlorophenyl)-propan-1-ol hydrochloride has a quantifiable effect on the SJL EAE model of multiple sclerosis, and suggesting that this molecule is a potential treatment for multiple sclerosis.
Claims

1. Use of a compound for the manufacture of a medicament for use in therapy of a neurodegenerative condition, wherein the compound is of formula (I)

\[
\begin{align*}
&\text{OH} \\
&\text{H} \\
&\text{R}_1 \\
&\text{R}_2 \\
&\text{R}_3 \\
&\text{N} \\
&\text{R}_4 \\
&\text{R}_5 \\
&\text{R}_6 \\
&\text{R}_7 \\
&\text{R}_8 \\
&\text{R}_9 \\
&\text{R}_{\text{g}} \\
\end{align*}
\]

wherein

\[ R_1 \text{ is } \text{CHR}_4\text{-OR}_6 \text{ or } \text{CHR}_4\text{-SR}_6, \text{ or aryI or heteroaryl optionally substituted with one or more groups } R_6; \]

\[ R_2 \text{ is alkyl or is part of a ring with } R_3; \]

\[ R_3 \text{ is H, alkyl or } \text{CH}_2 \text{ (when forming part of a ring with } R_2); \]

\[ R_4 \text{ is H or alkyl or is part of a ring with } R_5; \]

\[ R_5 \text{ is aryI or heteroaryl optionally substituted with } R_7; \]

\[ \text{each } R_6 \text{ is independently alkyl, CF}_3, \text{OH, Oalkyl, OCOalkyl, CONH}_2, \text{CN, halogen, } \text{NH}_2, \text{NO}_2, \text{NHCHO, NHCONH}_2, \text{NHSO}_2\text{alkyl, CONH}_2, \text{SOMe, SO}_2\text{NH}_2, \text{Salkyl, } \text{CH}_2\text{SO}_2\text{alkyl or OCONalkyl}_2; \]

\[ R_7 \text{ is } R_8 \text{ or } (\text{CH}_2)_n\text{OR}_8, R_9, \text{CF}_3, \text{OH, OR}_9, \text{OCOR}_9, \text{COR}_9, \text{COOR}_9, \text{CONH}_2, \text{CH}_2\text{CONH}_2, \text{CN, halogen, } \text{NH}_2, \text{NO}_2, \text{NHCHO, NHCONH}_2, \text{NHCONHR}_7, \text{NHCON(Rg)}_2, \text{NHCOR}_9, \text{NHCOaryl, NHSO}_2\text{Me, CONH}_2, \text{SMe, Salkyl or SO}_2\text{NH}_2; \]

\[ R_8 \text{ is } (\text{CH}_2)_n\text{OR}_9, (\text{CH}_2)_n\text{OR}_9, (\text{CH}_2)_n\text{COOR}_9 \text{ or } (\text{CH}_2)_n\text{COaryl}; \]

\[ R_9 \text{ is alkyl or cycloalkyl; and } \]

\[ n \text{ is } 1 \text{ to } 4; \]

or a salt thereof.

2. Use according to claim 1, wherein the condition is multiple sclerosis.

3. Use according to claim 1, wherein the condition is Alzheimer's disease.

4. Use according to claim 1, wherein the condition is Parkinson's disease.

5. Use according to any preceding claim, wherein the compound is chiral and is in the form of the enantiomer or diastereomer that has relatively little or no activity at the \( \alpha \) or \( \beta \) adrenoceptor.

6. Use according to any preceding claim, wherein the patient is also administered another therapeutic agent selected from cholinesterase inhibitors, steroids, interferons and glutamate receptor agents such as AMPA, kappa agents and NMDA antagonists.
7. Use according to claim 6, wherein compound (I) and said another agent are provided in combination.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC:

INV. A61K31/137 A61P25/00 A61P25/16 A61P25/28 A61P43/00

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used):

EPO-Internal, WPI Data, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>P,X</td>
<td>WO 2005/089741 A2 (ARAKIS LTD [GB]; BAXTER ANDREW DOUGLAS [GB]; BREW JOHN [GB]) 29 September 2005 (2005-09-29) abstract page 1, line 4 page 2, line 1 - page 3, line 11 page 6, line 7 - line 14 claims 1-17</td>
<td>1-7</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C

See patent family annex

Special categories of cited documents:

'A' document defining the general state of the art which is not considered to be of particular relevance
'E' earlier document but published on or after the international filing date
'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
'O' document referring to an oral disclosure, use, exhibition or other means
'P' document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search: 16 January 2007

Date of mailing of the international search report: 26/01/2007

Name and mailing address of the ISA:

European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx 31 651 epo nl.
Fax (+31-70) 349-3016

Authorized officer:

Taylor, Mark
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 01/62257 A2 (SEPRACOR INC [US]) 30 August 2001 (2001-08-30) abstract Scheme 1 page 3, line 5 - line 16 page 5, line 3 - line 25 page 5, line 29 - page 6, line 11 page 9, line 5 - line 9 page 9, line 14 - line 17 page 13, line 21 - page 14, line 5 page 27, line 17 - line 28 page 38, line 7 - page 39, line 29 claims 1-74</td>
<td>1-7</td>
</tr>
<tr>
<td>X</td>
<td>WO 00/51546 A2 (SEPRACOR INC [US]) 8 September 2000 (2000-09-08) abstract Scheme 1 page 4, line 13 - line 29 page 5, line 1 - line 14 page 7, line 29 - page 8, line 9 page 17, line 30 - page 18, line 13 claims 1-53; examples 1-8</td>
<td>1-7</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 2005089741 A2</td>
<td>29-09-2005</td>
<td>AU 2005224160 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2558126 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1725226 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0112484 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2415678 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1494540 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1680563 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 20030050 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0301688 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0206268 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PA03000397 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 20030120 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 523554 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 533997 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 359411 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK 152003 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003236297 A1</td>
</tr>
<tr>
<td>WO 0162257 A2</td>
<td>30-08-2001</td>
<td>AT 331520 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6926800 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2400482 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CZ 20022857 A3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 0300030 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003529563 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA02008093 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL 357389 A1</td>
</tr>
<tr>
<td>WO 0051546 A2</td>
<td>08-09-2000</td>
<td>AU 775642 B2</td>
</tr>
<tr>
<td>WO 2005044248 A</td>
<td>19-05-2005</td>
<td>NONE</td>
</tr>
</tbody>
</table>